Nitric oxide and septic shock

Area of Science:

• Biochemistry and Molecular Biology
• Physiology
• Pharmacology

Background:

• Nitric oxide (NO) is synthesized by three isoforms of NO synthase (NOS): constitutive endothelial NOS (eNOS), constitutive neuronal NOS (nNOS), and inducible NOS (iNOS).
• iNOS expression is upregulated by endotoxins (LPS) and cytokines, leading to excessive NO production.
• In septic shock, elevated iNOS-derived NO contributes to hypotension, vascular hyporeactivity, organ injury, and dysfunction.

Purpose of the Study:

• To investigate the role of iNOS in septic shock.
• To evaluate the therapeutic potential of iNOS inhibition in animal models of shock.
• To assess the effects of NOS inhibitors on human septic shock.

Main Methods:

• Studies in animal models of shock using iNOS protein expression inhibitors (e.g., dexamethasone) or selective iNOS activity inhibitors.
• Administration of nonselective NOS inhibitors (e.g., NG-methyl-L-arginine [L-NMMA]) in ongoing clinical trials for human septic shock.
• Assessment of hemodynamic effects and organ function in response to iNOS modulation.

Main Results:

• Inhibition of iNOS expression or activity demonstrated beneficial effects in animal models of septic shock.
• Inhibition of eNOS activity resulted in adverse effects, such as excessive vasoconstriction.
• Preliminary clinical data suggest that nonselective NOS inhibitors provide beneficial hemodynamic effects in human septic shock.

Conclusions:

• Targeting iNOS represents a promising therapeutic strategy for septic shock.
• Selective inhibition of iNOS, rather than nonselective NOS inhibition, may be crucial to avoid adverse effects.
• Further clinical investigation is warranted to confirm the efficacy and safety of NOS inhibitors in human septic shock.